3-METHYLMETHCATHINONE FOR THE TREATMENT OF PATIENTS IN PSYCHOTHERAPEUTIC TREATMENT
Patent Information
- Application Number
- DE602018080475
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2018-08-02
- Publication Date
- 2025-03-26
- Estimated Expiration
- 2038-08-02
AI Technical Summary
Traditional psychotherapy methods are often ineffective for individuals with severe mental health issues, and psychiatric medications have unpleasant and dangerous side effects, while existing drug-assisted psychotherapies face limitations such as anxiety and depression rebound effects from serotonergic drugs like MDMA.
Administering 3-methylmethcathinone (3-MMC) before, during, or after psychotherapeutic interventions to enhance therapeutic efficacy, promote empathy, and reduce distress in subjects with conditions like PTSD and anxiety disorders, using varying dosages and administration methods.
3-MMC-assisted psychotherapy improves patient rapport, reduces anxiety, and enhances therapeutic outcomes by promoting a sense of calm and creativity, effectively addressing obstacles to therapy progress and reducing distress in subjects with various mental health conditions.